NCT06880874View on ClinicalTrials.gov

A Clinical Study to Evaluate Enlicitide (MK-0616) Formulations in Healthy Adult Participants (MK-0616-035)

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 2, 2025

Primary Completion Date

May 16, 2025

Study Completion Date

May 31, 2025

Conditions
Healthy
Interventions
DRUG

Enlicitide

Oral Tablet

Trial Locations (1)

85283

Celerion ( Site 0001), Tempe

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT06880874 - A Clinical Study to Evaluate Enlicitide (MK-0616) Formulations in Healthy Adult Participants (MK-0616-035) | Biotech Hunter | Biotech Hunter